Wall Street’s Take On Health Care Exchanges
Health care exchanges for expanding insurance coverage as part of the Affordable Care Act will open in time to meet the law’s January 1 deadline, but their “robustness” and ease of use, at least initially, may be questionable, a panel of experts tells Wall Street.
You may also be interested in...
Ex-CMS administrator Thomas Scully, who has played an important role in moving forward some key federal health policy initiatives, including Medicare Part D, is optimistic about the Affordable Care Act’s impact on several sectors of health care, notably hospitals, and biopharma – in contrast to the industry’s general uncertainty and nervousness around implementation.
In a slow week for pharma deals, standouts included GSK’s wrap up with MorphoSys for a mid-stage rheumatoid arthritis drug, Pfizer’s deal to gain access to novel kinds of antibody drug-conjugates through platform company CytomX, and the first microbiome deal between a big pharma (Janssen) and a start-up, Second Genome.
Most health reform watchers have been tracking state votes on Medicaid expansion as a sort of scorecard on whether Obama Administration is winning or losing in health care reform. Push back from the states is making news now, but for biopharma sponsors, even a glass half full is a positive—and the long-term outlook is even brighter.